U.S. Markets closed

Momenta Pharmaceuticals, Inc. (MNTA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
15.30-0.15 (-0.97%)
At close: 4:00PM EDT

15.30 0.00 (0.00%)
After hours: 4:23PM EDT

People also watch
ALNYACORNBIXMDCOVNDA

Momenta Pharmaceuticals, Inc.

675 West Kendall Street
Cambridge, MA 02142
United States
617-491-9700
http://www.momentapharma.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees290

Key Executives

NameTitlePayExercisedAge
Mr. Craig A. WheelerChief Exec. Officer, Pres and Exec. Director1.27MN/A57
Dr. Ganesh Venkataraman Kaundinya Ph.D.Co-Founder, Chief Scientific Officer & Sr. VP648.27kN/A50
Mr. Scott M. StorerChief Financial Officer, Sr. VP & Treasurer40.53kN/AN/A
Mr. Bruce A. Leicher J.D.Sr. VP, Gen. Counsel and Corp. Sec.620.78kN/A61
Dr. Young T. Kwon Ph.D.Sr. VP of Corp. Devel. & StrategyN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company’s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company’s novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy; M281, a fully-human monoclonal antibody that blocks the neonatal Fc receptor; and M230, a selective immunomodulator of Fc receptors candidate. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Momenta Pharmaceuticals, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 6; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.